Sprint Bioscience AB
STO:SPRINT
Sprint Bioscience AB
Sprint Bioscience AB is a pharmaceutical company, which engages in the research and development of drug for cancer. The company is headquartered in Huddinge, Stockholm. The company went IPO on 2014-11-07. The company is engaged in the development of oncology therapeutics, focusing on cancer metabolism and liquid signaling. The firm's research is based on its fragment based drug discovery (FBDD) platform, which enables rapid indentifying of molecules with properties suitable for drug development. Its pipeline is divided in two research areas: cancer metabolism and autophagy, comprising products in the phases of establishing FBDD project and in the in vivo development. The Company’s strategy involves out-licensing or collaborating at an early stage of drug discovery in order to focus on current market needs.
Sprint Bioscience AB is a pharmaceutical company, which engages in the research and development of drug for cancer. The company is headquartered in Huddinge, Stockholm. The company went IPO on 2014-11-07. The company is engaged in the development of oncology therapeutics, focusing on cancer metabolism and liquid signaling. The firm's research is based on its fragment based drug discovery (FBDD) platform, which enables rapid indentifying of molecules with properties suitable for drug development. Its pipeline is divided in two research areas: cancer metabolism and autophagy, comprising products in the phases of establishing FBDD project and in the in vivo development. The Company’s strategy involves out-licensing or collaborating at an early stage of drug discovery in order to focus on current market needs.
